Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like <b>Genetic Technologies</b> Announces Comprehensive Review Of Strategic Alternatives August 27, 2017 Intersect ENT To Report First Quarter 2017 Financial Results April 16, 2017 Bay Area's Dynavax Quietly Shops Around Its Almost-Approved Hep B Vaccine October 1, 2017
